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Abstract
Background: Family-based association testing is an important part of genetic epidemiology. Tests
are available to include multiple siblings, unaffected offspring, and to adjust for environmental
covariates. We explore a susceptibility residual method of adjustment for covariates.
Results: Through simulation, we show that environmental adjustments that down-weight persons
who are "destined" to be affected decrease the power to detect genetic association. We used the
residual adjusted method on the Framingham Heart Study offspring data, provided for Genetic
Analysis Workshop 13, and got mixed results.
Conclusion: When the genetic effect and environmental effects are independent, a susceptibility
residual method of adjustment for environmental covariates reduces the power of the association
test. Further study is necessary to determine if residual adjustment is appropriate in more complex
disease models.

Background
Family-based association tests, such as Spielman's transmission disequilibrium test (TDT) [1] rely on affection
status and marker phenotypes for determination of
within-family association of disease and allele. The original version of the TDT, still frequently used in association
studies of complex phenotypes, scores only affected offspring. The modified family-based association test (FBAT)
method by Horvath et al. [2,3] can use a covariateadjusted phenotypic value allowing unaffected offspring
to contribute to the test statistic [4,5]. The covariateadjusted phenotypic value, T = Y - µ, adjusts Y, a dichotomous indicator of affection status, by µ, a covariate value

based on a dichotomous trait, measured trait value (e.g.,
glucose), or age-dependent phenotypic value.
To expand this covariate adjustment to a more general setting, we propose the use of a susceptibility score. For
instance, we model affection status on the covariates of
interest using logistic regression and then use the susceptibility residual as a measure of deviance from the predicted outcome. Genotypes are excluded from the
regression because we are not adjusting for genetic effects.
Our logistic model differs only slightly from the suggested
calculation of T, such that T = Y - p, where p is the estimated predicted probability from the logistic model. In
this context, we call T the susceptibility residual.
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A concern with the covariate adjustment method in FBAT
is that persons with low deviance from the predicted outcome are heavily down-weighted. The assumption is that
persons with low deviance were susceptible to affection
regardless of genetic makeup and therefore should not
contribute fully to the association test. In the extreme case
in which the affection status is predicted perfectly by the
covariate in FBAT, that individual contributes no information to the result. Through simulation we explore the
power and type I error rates of the adjusted Horvath test
compared to the unadjusted version of the same test. We
vary the influence of the genetic component and the nongenetic (covariate) component from no influence to an
increased odds-ratio of 4.95. This comparison of methods
allows us to investigate the advantages and disadvantages
of covariate adjustment. Briefly stated, we found that for
those cases in which a moderately strong genetic influence
is determinative, adjustment for environmental cofactors
can reduce the power to detect association between the
disease and the disease allele. We apply the susceptibility
residual adjustment to the Framingham Heart Study offspring data, available for the Genetic Analysis Workshop
13 (GAW13), to observe the effects of adjustment on nonsimulated data.

Methods
Data simulation and simulated disease onset
In each replicate 100 families were generated with two
parents and 2 to 10 offspring, according to a truncated
Poisson distribution (λ = 4), such that each family contained at least one affected offspring. Parental genotypes
were determined by random selection assuming HardyWeinberg equilibrium and random inheritance was used
for determining offspring genotypes. For these simulations, a bi-allelic marker was considered such that the disease allele has a population frequency of 0.15. Offspring
exposure to the covariate was randomly determined using
a population exposure rate of 0.20. Disease status was
determined by the following logistic model:

(

Pr ( disease | x1, x2 ) = e α +β1x1 +β2 x2

) ( 1 + e α +β x +β x ) ,
1 1

2 2

where α ≈ -2.9, such that Pr(disease|x1 = x2 = 0) = 0.05 and
β1, β2 are the regression coefficients corresponding to the
indicator variables x1 and x2 for raised genetic and environmental risk, respectively. The β values were varied at
intervals of 0.2 from 0.0, no risk, to 1.6, increased odds of
4.95, thus creating nine levels of the genetic effect and
nine levels of the covariate effect. The probability of disease calculated by the above model was compared to a
random number selected from a uniform [0,1] distribution. If the probability of disease onset is greater than the
random number, then the individual in question is
labeled as affected.

Generation of residuals
Residuals were created from a logistic model with affection status as the outcome and a single dichotomous covariate indicating exposure. Since each family has at least
two offspring, a robust sampling method was used to
avoid issues of correlated data within families. The logistic
model was fitted 100 times on randomly selected subsets
of the offspring, such that each family was represented by
a single offspring. Average parameter values from the 100
cycles were used to generate residuals for each offspring.
FBAT
A bi-allelic marker with dominant disease inheritance was
simulated and thus the dominant model and bi-allelic test
mode were used in FBAT. We ran FBAT twice on each simulated data set to observe the results from both the covariate adjusted and unadjusted affection status tests.
Significant results were determined by a p-value less than
or equal to 0.05 for the disease allele. Power was calculated as the frequency of significant results per 1000
cycles. The type I error rate of the model was calculated as
the frequency of significant results per 1000 cycles when
no genetic effect was modeled.
Framingham Heart Study offspring data
To demonstrate our assumptions from the simulated data
in a real world setting, we applied the FBAT procedure to
the Framingham Heart Study offspring data, available for
GAW13, using offspring from Cohort 2 and their parents
if available. The disease status of interest was hypertension, determined by systolic blood pressure measurement
over 140 for three consecutive exams or by the administration of anti-hypertensive drugs. We used regular smoking
as the environmental covariate, determined by a selfreport of smoking at least 20 cigarettes (1 pack) per day
for at least one of the five exams.

The genotypes of interest were determined using a
genome scan with FBAT on a random selection of nuclear
families. We selected markers GATA48G07A (10q25.3)
and GGAA5D10 (10q26.13) on chromosome 10, and
GGAA7D11 (17q11.2) on chromosome 17 because each
showed a significant association to hypertension using
FBAT. Also, literature suggests association for neighboring
regions on chromosome 10 [6,7] and chromosome 17 [810]. As negative controls, we selected markers
GATA88F09 (10p15.3), at least 130 cM away from the
region of interest on chromosome 10, and 217YD10
(17q25.3), approximately 70 cM away from the region of
interest on chromosome 17. Neither negative control
marker had shown significant association with hypertension in the FBAT genome scan and thus we used them to
explore false positive rates in the nonsimulated data.
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To match the methods of the simulation, FBAT was run
using a dominant model of inheritance and the bi-allelic
testing mode. Significance of an allele was determined by
p < 0.05. The marker was tested on 100 random selections
of nuclear families from the full pedigree data. Thus correlation between families within a pedigree was avoided.
The program default minimum of 10 informative families
for testing was maintained in these FBAT runs.

Results
Power and type I error
The power of the FBAT procedure was determined for each
parameter set by testing 1000 simulated data sets, 100
families each, and recording the frequency of significant
results (p < 0.05 for the disease allele). Figure 1 plots the

power of the test for the adjusted versus the unadjusted
method at each level of risk combinations. Formal testing
of the two methods, at each of the eight non-zero levels of
genetic effect, shows that the unadjusted method has consistently higher power than the adjusted method (p <
0.05, with Benjamini-Hochberg correction for multiple
comparisons). The type I error rate of the model was
determined at varying covariate effect levels, using no
genetic effect. Figure 2 plots the type I error rates of the test
for the adjusted versus unadjusted methods at each of the
nine covariate levels. The type I error rates did not differ
significantly between the two test methods when
compared using a Wilcoxon signed rank test on the pairwise differences (p = 0.71). Thus we find no change in type
I error rates from the covariate adjustment.
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Figure
Power Plot of power for the adjusted test versus the unadjusted test at varying genetic risk levels. The legend lists the odds of
disease, given inheritance of the disease allele, for each risk cluster. Each of the nine covariate risk levels is represented within
a single genetic risk cluster. There is a tendency for higher environmental risk to decrease the power within a genetic risk cluster (not shown).
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Figure
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2 rates
Type I error rates Plot of type I error rates for the adjusted test versus the unadjusted test at varying covariate risk levels.
The legend lists the odds of disease, given exposure to the covariate, at each point. The type I error rates are not significantly
different from 5% for either the adjusted or unadjusted test (p > 0.5). Likewise, the error rates are not significantly different
between tests (p = 0.71).

Framingham Heart Study offspring data
The comparison of the test methods, unadjusted versus
adjusted, on the Framingham Heart Study offspring data
shows mixed results. Tables 1,2,3 list the proportion of
tests that produced a significant result for each allele, at
markers GATA48G07A (c10), GGAA5D10 (c10), and
GGAA7D11 (c17), respectively. One hundred random
selections of nuclear families were tested and a minimum
of 10 informative families at an allele were required for
testing. Alleles for which no tests were done are excluded
from Tables 1,2,3. Note the increase in the number of
informative families, per allele, for the adjusted method
compared to the unadjusted method. The covariateadjusted method provides more information to the phenotype and thus most alleles have twice as many informative families compared to the unadjusted method.

In Table 1, marker GATA48G07A, allele 350 shows 100%
significance and is under-transmitted for both testing
methods. However, the unadjusted test was only run on
47 of the 100 random samples due to a lack of informative families (median N = 9). The increased information
in the adjusted test allowed it to run on all 100 random
samples (median N = 23). Allele 362 is over-transmitted
and shows 65% significance in the unadjusted method
and only 42% significance in the adjusted method, suggesting reduced power in the adjusted method.
In Table 2, marker GGAA5D10, we see increased transmission for alleles 93 and 109. The unadjusted test had 66%
significant tests for allele 93 versus only 8% significance
with the adjusted test. Likewise, the unadjusted test had
91% significant tests for allele 109 versus only 75% significance with the adjusted test. However, the adjusted test
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Table 1: Results for marker GATA48G07A (chromosome 10) Results from FBAT analysis of the Framingham Heart Study offspring
data using the unadjusted test for association between marker GATA48G07A (chromosome 10) and high blood pressure and the
adjusted test using regular smoking (>1 pack/day) as a covariate.

Allele
NameA
346
350
354
358
362
366
370
374
378
AAlleles

Unadjusted Test

Adjusted Test

Frequency

No. Tests

% Significance

MedianB N

No. Tests

% Significance

MedianB N

0.028
0.063
0.208
0.309
0.149
0.097
0.041
0.050
0.041

0
47
100
100
100
100
0
76
0

-100
0
0
65
0
-0
--

6
9
22
29
21
15
4
10
7

100
100
100
100
100
100
100
100
100

0
100
0
0
42
1
0
0
0

13
23
52
61
54
35
16
23
15

330, 338, 342, 382, and 386 did not have any informative tests. BN = median number of informative families.

Table 2: Results for marker GGAA5D10 (chromosome 10) Results from FBAT analysis of the Framingham Heart Study offspring data
using the unadjusted test for association between marker GGAA5D10 (chromosome 10) and high blood pressure and the adjusted test
using regular smoking (>1 pack/day) as a covariate.

Allele

Unadjusted Test

Adjusted Test

NameA

Frequency

No. Tests

% Significance

MedianB N

No. Tests

% Significance

MedianB N

93
101
105
109
113
117
121
125
129

0.031
0.081
0.179
0.366
0.118
0.102
0.083
0.026
0.010

100
100
100
100
100
100
100
100
0

66
2
3
91
0
0
0
0
--

17
31
52
55
36
34
25
11
5

100
100
100
100
100
100
100
100
7

8
0
22
75
0
0
0
0
14

28
66
107
138
80
70
62
26
8

AAlleles

97 and 133 did not have any informative tests. BN = median number of informative families.

Table 3: Results for marker GGAA7D11 (chromosome 17) Results from FBAT analysis of the Framingham Heart Study offspring data
using the unadjusted test for association between marker GGAA7D11 (chromosome 17) and high blood pressure and the adjusted test
using regular smoking (>1 pack/day) as a covariate.

Allele

Unadjusted Test

Adjusted Test

NameA

Frequency

No. Tests

% Significance

MedianB N

No. Tests

% Significance

MedianB N

262
266
270
274
278
282
286
290
262

0.099
0.175
0.091
0.135
0.206
0.157
0.083
0.099
00.032

100
100
100
100
100
100
100
100
100

0
0
0
87
0
0
35
0
0

26
45
35
40
48
43
31
13
26

100
100
100
100
100
100
100
100
100

46
0
0
89
0
0
6
0
46

63
94
70
86
103
90
59
25
63

AAlleles

254, 258, 283, and 294 did not have any informative tests. BN = median number of informative families.
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detected significantly decreased transmission in allele 105
in 22% of the 100 random samples versus only 3% in the
unadjusted test.
In Table 3, marker GGAA7D11, we see increased transmission in allele 286 with 35% significance using the unadjusted test versus only 6% significance in the adjusted test.
Allele 274 showed decreased transmission with 87% significance using the unadjusted FBAT test compared to
89% significance using the adjusted test. Significantly
increased transmission was shown for allele 262 in 46%
of the 100 random samples using the adjusted test.
Increased transmission at allele 262 was not detected by
the unadjusted test.
Results for the negative control markers show low falsepositive rates for both methods, data not shown. At
marker GATA88F09, the negative control on chromosome
10, the unadjusted test showed no significant results (0%
false positive) and the adjusted test showed a low number
of significant results (0–7% false positive, mean < 2.5%)
on the five alleles tested. At marker 217YD10, the negative
control on chromosome 17, the unadjusted test showed
no significant results (0% false positive) for all but one of
the seven alleles tested (30% false positive). The adjusted
test at marker 217YD10 showed a low number of significant results (0–8% false positive, mean < 1%) for the 11
alleles tested.

Discussion
In simulated data the covariate adjustment procedures in
FBAT demonstrated the expected loss in power attributable to the "discounting" of information for affected persons who had a high prior environmental risk of disease.
This phenomenon of "discounting" has the paradoxical
attribute that more definitive information about the environmental contributors to a trait may actually cause more
difficulty in detecting a genetic signal.
Interpretation of the comparison between the adjusted
and unadjusted versions of the FBAT test when applied to
real data is difficult primarily because the suggested loss of
power was not uniform across marker loci. In particular,
at the three markers a total of eight alleles were detected
by one or both of the tests, of which four were detected
more frequently with the unadjusted test and three were
detected more frequently with the adjusted test. All four of
the alleles detected more frequently by the unadjusted test
had increased transmission. Yet only two of the three alleles detected more frequently by the adjusted test were
under-transmitted and allele 350 on marker
GATA48G07A, detected in 100% of the tests for both
methods, is over-transmitted. Also, no pattern arises
between allele frequency and the frequency of detection
by either test method, unadjusted or adjusted.

http://www.biomedcentral.com/1471-2156/4/s1/S49

The negative controls suggest that the false-positive rates
for both tests are low; however, the spurious 30% falsepositive rate presumed for one allele on marker 217YD10
(chromosome 10) for the unadjusted test lends doubt to
the results for alleles showing significant association at
low frequencies. In particular the significance of allele 286
on marker GGAA7D11 (Table 3) may be spurious. Yet,
false-positive rates were low (0–8% false positive) for all
alleles when the adjusted test was used so it is not appropriate to disregard all low frequency significant results.
Thus false-positive rates cannot explain the discrepant
results between the two tests.
The mixed results, regarding power loss in the susceptibility residual adjusted test, from the three markers of interest could reflect variation in the extent of genetic
determination of the trait or possibly interaction between
genetic and environmental factors that is not specified in
our model. Further simulations, accounting for variable
influence of different alleles at a marker and gene ×
environment interaction, would be needed to explain this
set of results more satisfactorily.

Conclusions
When the genetic effect and environmental effects are
independent, a susceptibility residual method of adjustment for environmental covariates reduces the power of
the association test. Results of the method comparisons in
the Framingham data are not conclusive and further study
is necessary to determine if susceptibility residual adjustment is appropriate in more complex disease models.
Our results should not be taken as indication that the
FBAT adjustment should be avoided. Further simulations,
involving correlation between genetic and covariate influences, are being explored in an effort to find situations in
which the susceptibility residual is beneficial for the
adjustment of covariate effects. Likewise, the reader
should note that we have explored only one method of
covariate adjustment for family-based association testing.
We hope that our efforts in this matter will encourage others to evaluate covariate adjustment measures, since we
believe that accounting for nongenetic influences is
important in modeling complex diseases.
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